Cushing Syndrome

Endocrinology
5
Pipeline Programs
3
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Corcept Therapeutics
Corcept TherapeuticsCA - Redwood City
3 programs
1
1
1
RelacorilantPhase 31 trial
relacorilantPhase 21 trial
Dabigatran EtexilatePhase 11 trial
Active Trials
NCT05347979Completed30Est. Jul 2022
NCT03604198Active Not Recruiting125Est. Dec 2026
NCT03697109Completed152Est. Apr 2024
Recordati
RecordatiFrance - Saint-Victor
1 program
1
LCI699Phase 21 trial
Active Trials
NCT03708900Recruiting12Est. Jul 2027
Crinetics Pharmaceuticals
1 program
1
atumelnantPhase 1/21 trial
Active Trials
NCT05804669Recruiting18Est. Oct 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Corcept TherapeuticsRelacorilant
RecordatiLCI699
Corcept Therapeuticsrelacorilant
Crinetics Pharmaceuticalsatumelnant
Corcept TherapeuticsDabigatran Etexilate

Clinical Trials (5)

Total enrollment: 337 patients across 5 trials

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Start: Nov 2018Est. completion: Apr 2024152 patients
Phase 3Completed

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Start: Apr 2021Est. completion: Jul 202712 patients
Phase 2Recruiting

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Start: May 2018Est. completion: Dec 2026125 patients
Phase 2Active Not Recruiting

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Start: Oct 2023Est. completion: Oct 202618 patients
Phase 1/2Recruiting

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Start: May 2022Est. completion: Jul 202230 patients
Phase 1Completed

Related Jobs in Endocrinology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 337 patients
3 companies competing in this space